Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4160088
Max Phase: Preclinical
Molecular Formula: C72H131N17O17
Molecular Weight: 1506.94
Molecule Type: Unknown
Associated Items:
ID: ALA4160088
Max Phase: Preclinical
Molecular Formula: C72H131N17O17
Molecular Weight: 1506.94
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCC)NC(=O)C[C@H](CO)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)C[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)C[C@@H]1CCCN1C(C)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)CC
Standard InChI: InChI=1S/C72H131N17O17/c1-12-17-24-47(34-57(76)94)78-66(100)53(28-20-22-32-74)83-68(102)51(26-18-13-2)81-58(95)35-49(41-91)80-71(105)64(44(9)15-4)88-62(99)39-77-70(104)63(42(6)7)86-59(96)36-48(40-90)79-67(101)54(29-30-56(75)93)84-72(106)65(45(10)16-5)87-61(98)38-55(43(8)14-3)85-69(103)52(27-19-21-31-73)82-60(97)37-50-25-23-33-89(50)46(11)92/h42-45,47-55,63-65,90-91H,12-41,73-74H2,1-11H3,(H2,75,93)(H2,76,94)(H,77,104)(H,78,100)(H,79,101)(H,80,105)(H,81,95)(H,82,97)(H,83,102)(H,84,106)(H,85,103)(H,86,96)(H,87,98)(H,88,99)/t43-,44-,45-,47-,48+,49+,50-,51-,52-,53-,54-,55-,63-,64-,65-/m0/s1
Standard InChI Key: OBRFEIVNTNASOE-ZXQFYVFGSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1506.94 | Molecular Weight (Monoisotopic): 1505.9909 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. de Lucio H, Gamo AM, Ruiz-Santaquiteria M, de Castro S, Sánchez-Murcia PA, Toro MA, Gutiérrez KJ, Gago F, Jiménez-Ruiz A, Camarasa MJ, Velázquez S.. (2017) Improved proteolytic stability and potent activity against Leishmania infantum trypanothione reductase of α/β-peptide foldamers conjugated to cell-penetrating peptides., 140 [PMID:29017116] [10.1016/j.ejmech.2017.09.032] |
Source(1):